Blog
Case study highlights Parkinson’s-like toxicity after BCMA-directed CAR T-cell therapy
Clinicians treating patients with CAR T cells have become adept
March 6, 2022
Menu
Clinicians treating patients with CAR T cells have become adept
The adoptive transfer of T lymphocytes reprogrammed to target tumour
CAR-M is a therapy that begins with the isolation of
For 17 years, Thomas Blankenstein has been working on his
A group of researchers set out to characterize the genotypic
CAR-T cell therapy, which received FDA approval in 2017, are
Solid tumors are surrounded by an immunosuppressive tumor microenvironment. Therefore,
The CAR T-cell therapy idecabtagene vicleucel (ide-cel; Abecma) continues to
Alternative oxidase (AOX) has been identified as a potential therapeutic
